OncoMatch/Clinical Trials/NCT07710885
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Is NCT07710885 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for biliary tract cancer.
Treatment: Futibatinib · Zimberelimab · Durvalumab · Pembrolizumab · Gemcitabine · Cisplatin — To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: FGFR inhibitor (futibatinib)
Has prior Fibroblast Growth Factor Receptor (FGFR)-directed therapy including futibatinib
Cannot have received: immune checkpoint inhibitor (anti-PD-L1, anti-PD-1, anti-CTLA-4, anti-TIGIT)
Has prior treatment with an anti-Programmed Death Ligand 1 (PD-L1), anti-Programmed Cell Death Protein 1 (PD-1), anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT), or other immune checkpoint inhibitor (ICI) or agonist as monotherapy or in combination
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07710885 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FGFR inhibitor, immune checkpoint inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages